Regencell Bio offers traditional medication in ASEAN countries

Regencell Bioscience Holdings has announced that Regencell Bioscience, the company’s wholly-owned subsidiary in Hong Kong, has entered into a joint venture agreement with Honor Epic Enterprises. The joint venture (JV) is expected to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. In March 2020, Sik-Kee Au, Regencell’s strategic partner TCM practitioner, started to develop a Traditional Chinese Medicine (TCM) treatment formula targeting COVID-19 patients. So far, 12 patients (suspected or confirmed COVID-19 cases) have been treated, and their health records showed improvements after an average treatment period of 5 days. Regencell will own 60 per cent of the JV with a customary drag-along option. The principal business of the JV shall be to trade, manufacture, market and distribute TCM formulae products, procure, enable, provide or support the treatment of COVID-19 using TCM in the ASEAN countries, India, Japan, Australia and New Zealand.